Grant supplements the $292 thousand one-year NIH/SBIR grant to develop this indication Knee arthroplasty is another example of the broad potential utility of Bionanomatrix™ to improve patient outcomes BIRMINGHAM, Ala., July 09, 2024 (GLOBE NEWSWIRE) -- Endomimetics, the developer of Bionanomatrix™, a peptide-based biomaterial used to promote healing and improve outcomes following medical device implantation and other procedures, announced today the awarding of a $100,000 grant from Innovate Alabama to support research to develop and evaluate the potential of a Bionanomatrix™ formulation to reduce infectious and inflammatory complications that occur following knee replacement. The grant is supplemental to the previously awarded $292 thousand one-year NIH/SBIR grant to support this indication. These grants provide further evidence of the broad utility of the Bionanomatrix™ to improve performance and outcomes of implantable medical devices. "Our Bionanomatrix™ technology emerged from bioengineering work conducted at the University of Alabama at Birmingham and is part of a state-wide effort to foster the continued development of the biomedical industry in Alabama," said Joseph Garner, Ph.D., Chief Executive Officer of Endomimetics. "We are very grateful that Innovate Alabama also sees the value of our platform and its potential to improve patient outcomes following medical device implantation or interventional surgeries. With this grant we continue to focus on the potential of Bionanomatrix™ to improve the success rate for patients needing knee replacements while also advancing the other applications for the platform." Osteoarthritis (OA) is a degenerative joint disease that ...